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120risk-reduction beneﬁts that outweigh the potential
for adverse effects and drug-drug interactions, and
consider patient preference.” Based on the ﬁndings of
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial) (3), ezetemibe
would qualify as a nonstatin to be considered with a
lower intensity, but tolerated statin in high-risk groups
such as those with coronary atherosclerotic disease.
Thus, the data from this intravascular ultrasound trial
are consistent with what the guidelines recommend if
a high-intensity statin cannot be tolerated.
Lastly, there is an implied misconception of the
panel’s recommendation regarding lipid targets. The
ACC/AHA guidelines stated that “the Expert Panel
makes no recommendations for or against speciﬁc
LDL-C or non–HDL-C targets for the primary or sec-
ondary prevention of ASCVD.” The guidelines go
beyond stating that lower LDL-C is better; rather they
recommend a strategy for achieving a lower LDL-C
that can be safely attained with therapies (lifestyle
and medication) proven to provide acceptable net
beneﬁt. For example, trials of niacin added to statin
therapy that achieved lower LDL-C levels by adding
Niacin as compared to placebo, did not show net
beneﬁt. Thus, the cholesterol guidelines endorse
“lower is better, but it matters how you get there and
whether the beneﬁt outweighs the risk for that
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Stated MattersWe have read with great interest the letter by
Dr. Stone and colleagues commenting on our recent
paper (1), and we greatly appreciate their valuable
comments on the interpretation of 2013 American
College of Cardiology/American Heart Association
(ACC/AHA) cholesterol guideline (2). Especially per-
taining to the “Fire and Forget It” concept mislead-
ingly disseminated among the clinicians, it is of
clinical importance that the expert panel members
clearly recommend in this letter a follow-up lipid
panel 4 to 12 weeks after initiation of statin therapy
to assess both response to therapy (the anticipated
response to high-intensity statin therapy was given
as a $50% reduction in low-density lipoprotein
cholesterol [LDL-C]) and as a baseline for adherence.
In addition, Drs. Stone, Lloyd-Jones, and Smith
emphasized that the ACC/AHA guideline endorse
“lower is better, but it matters how you get there and
whether the beneﬁt outweighs the risk for that
patient.”
In terms of the speciﬁc LDL-C treatment goals in
secondary prevention, we totally agree with the
guideline statement: the expert panel was unable to
ﬁnd robust evidence to support continued use of
speciﬁc LDL-C treatment targets (<100 mg/dl or
<70 mg/dl). In a recent meta-analysis of statin trials
(3), however, among 38,153 participants treated with
high-dose statin therapy, patients who achieve very
low LDL-C levels have a lower risk for major cardio-
vascular events than do those achieving moderately
low levels, and >40% did not reach an LDL-C
target <70 mg/dl, reafﬁrming “the lower, the better”
and the limitation of statin monotherapy. Further-
more, based on the safety and signiﬁcant clinical net
beneﬁt of combination of statin/ezetimibe evidenced
by IMPROVE-IT (Improved Reduction of Outcomes
Vytorin Efﬁcacy International Trial) (4) and PRECISE-
IVUS (Plaque Regression With Cholesterol Absorption
Inhibitor or Synthesis Inhibitor Evaluated by Intra-
vascular Ultrasound) (1) trials in contrast with
HPS2-THRIVE (Heart Protection Study 2–Treatment of
HDL to Reduce the Incidence of Vascular Events) trial
(5), ezetimibe added to statin therapy would qualify
as a promising non-statin agent to be considered in
high-risk patients such as those with coronary
atherosclerotic disease.
Finally, we would like to thank Drs. Stone,
Lloyd-Jones, and Smith again for the letter which
promoted for us and the readers of our article
the accurate interpretation of the 2013 ACC/AHA
cholesterol guideline.
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Impact of Pre-Operative
Malperfusion on
Acute Type A Dissection
The Modiﬁed Penn ClassiﬁcationWe read with great interest the recent article re-
ported by Czerny et al. (1) who performed an
analysis of a large database to address an importantissue showing that malperfusion remained a severe
clinical condition with strong potential for adverse
outcomes in patients of acute type A aortic
dissection (ATAAD) undergoing surgery while the
impact differed substantially in accordance with the
number and the type of organ malperfusion
involved. Therefore, they proposed a classiﬁcation
system of “complicated” and “uncomplicated”
ATAAD to help predict risk of outcomes. We want
to congratulate the investigators for shedding light
on the important issue of the impact of malperfu-
sion on operative mortality risk for patients with
ATAAD. The investigators provided valuable scien-
tiﬁc evidences which conﬁrmed and extended the
viewpoint of ischemic consequences of organ mal-
perfusion and end-organ dysfunction that compro-
mised survival (2,3), although some investigators
still argued that generalized ischemia in ATAAD
predicted early surgical outcomes only (4). The
issue of generalized ischemia caused by circulatory
collapse, distinct from localized organ ischemia, is a
very well taken point to be emphasized as the most
important predictor of outcome after surgical repair
of ATAAD and associated with the highest in-
hospital mortality regardless of treatment strategy
(3–5). In 2009, Augoustides et al. (2) reported an
observational study of mortality risk stratiﬁcation
by ischemic presentation in patients with ATAAD,
so-called Penn classiﬁcation, which has been vali-
dated by subsequent investigators (see references 1
and 5 in Chien et al. [5]) and has shown merit to be
a useful risk assessment system in predicting
ATAAD-related in-hospital mortality (4,5). Never-
theless, Penn classiﬁcation might still underesti-
mate the surgical risk of ATAAD in the setting with
critical organ-speciﬁc ischemia (including mesen-
teric ischemia, sustained major cerebral ischemia,
and coronary malperfusion). From this point of
view, we have proposed to modify the original
Penn classiﬁcation and suggested to divide the
Penn class Ab into subclasses Ab-1 and Ab-2
(Table 1) (5). Based on this consideration, we
studied the relationship of ischemic presentations
to 30-day mortality after surgical repair in 179 pa-
tients from 1997 to 2014 (mean age, 59  12 years;
124 men; classes Aa [n ¼ 60], Ab-1 [n ¼ 44], Ab-2
[n ¼ 27], Ac [n ¼ 10], and Abc [n ¼ 38]). It was
found that subclass Ab-2 had much higher mortality
rate than that of subclass Ab-1 (22.2% vs. 2.3%),
however, without statistical signiﬁcance (p ¼ 0.175).
One possible explanation is the small number of
our patients suffered from localized malperfusion
(Ab-1 or Ab-2). Nevertheless, we do think that
subclass Ab-2 remains a surgical challenge and is
